Spinal Cord Injury - Pipeline Review, H2 2017

Date: October 17, 2017
Pages: 200
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: SF194FF34DCEN
Leaflet:

Download PDF Leaflet

Spinal Cord Injury - Pipeline Review, H2 2017
Spinal Cord Injury - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury - Pipeline Review, H2 2017, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape.

Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinal Cord Injury - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Spinal Cord Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinal Cord Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 8, 1, 29 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 15 and 2 molecules, respectively.

Spinal Cord Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Cord Injury (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Spinal Cord Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Spinal Cord Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Spinal Cord Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Cord Injury (Central Nervous System)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Spinal Cord Injury (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Spinal Cord Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Spinal Cord Injury - Overview
Spinal Cord Injury - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Spinal Cord Injury - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Spinal Cord Injury - Companies Involved in Therapeutics Development
AbbVie Inc
Acorda Therapeutics Inc
Aevi Genomic Medicine Inc
Apollo Endosurgery Inc
Asterias Biotherapeutics Inc
Athersys Inc
BioArctic AB
BioAxone BioSciences Inc
Biogen Inc
CSL Ltd
CSPC Pharmaceutical Group Limited
Genervon Biopharmaceuticals LLC
Hemostemix Inc
Histocell SL
K-Stemcell Co Ltd
Kadimastem Ltd
Kringle Pharma Inc
MandalMed Inc
Mapreg SAS
Neuralstem Inc
Neuronax SAS
New World Laboratories Inc
Pharmicell Co Ltd
PixarBio Corp
RDD Pharma Ltd
RespireRx Pharmaceuticals Inc
SanBio Inc
Spectrum Pharmaceuticals Inc
Stemedica Cell Technologies Inc
TissueGene Inc
Tumorend LLC
Vertex Pharmaceuticals Inc
Vicore Pharma AB
Spinal Cord Injury - Drug Profiles
ABT-555 - Drug Profile
APO-1 - Drug Profile
ASTOPC-1 - Drug Profile
AX-007 - Drug Profile
BA-277 - Drug Profile
BA-434 - Drug Profile
C-21 - Drug Profile
Cell Therapy for Spinal Cord Injury - Drug Profile
Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile
Cellgram-SCI - Drug Profile
CHEC-9 - Drug Profile
chondroitinase ABC nanosphere - Drug Profile
CLR-01 - Drug Profile
CM-101 - Drug Profile
CX-1739 - Drug Profile
CX-717 - Drug Profile
Drug for Spinal Cord Injury - Drug Profile
Drugs to Inhibit ROCK for Spinal Cord Injury - Drug Profile
ES-135 - Drug Profile
Fusion Protein to Antagonize EPHA4 for Amyotrophic Lateral Sclerosis, Acute Spinal Cord Injury, Sepsis and Ischemia Reperfusion Injury - Drug Profile
Gene Therapy for Spinal Cord Injury and Neurodegenerative Diseases - Drug Profile
glyburide - Drug Profile
GM-603 - Drug Profile
HBN-1 - Drug Profile
HC-016 - Drug Profile
ICCN-100 - Drug Profile
immune globulin (human) - Drug Profile
IMS-001 - Drug Profile
IMS-002 - Drug Profile
JM-4 - Drug Profile
KP-100IT - Drug Profile
laflunimus - Drug Profile
LM-11A31BHS - Drug Profile
LPA-181 - Drug Profile
Lpathomab - Drug Profile
MAP-4343 - Drug Profile
Monoclonal Antibody to Inhibit Connexin 43 for Spinal Cord Injury - Drug Profile
NCP-01 - Drug Profile
Neu-2000 - Drug Profile
NeuroRelease SCI - Drug Profile
neurovitas - Drug Profile
NgR(310)ecto-Fc - Drug Profile
NOVO-117 - Drug Profile
NSI-566 - Drug Profile
NWL-53 - Drug Profile
NX-210 - Drug Profile
Oligonucleotide for Central Nervous System and Metabolic Disorders - Drug Profile
oxymetazoline hydrochloride - Drug Profile
Peptide to Inhibit CSPG for Spinal Cord Injury and Neurodegenerative Diseases - Drug Profile
PF-05285401 - Drug Profile
Proteins to Activate BGLAP for Spinal Cord Injury and Autoimmune Disorders - Drug Profile
Q-Cells - Drug Profile
R-801 - Drug Profile
Recombinant Chondroitinase to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury - Drug Profile
SB-618 - Drug Profile
SB-623 - Drug Profile
SC-0806 - Drug Profile
Small Molecules for Spinal Cord Injury - Drug Profile
Small Molecules to Block Voltage-Gated Potassium Channel for Spinal Cord Injury and Multiple Sclerosis - Drug Profile
SPI-1620 - Drug Profile
Stem Cell Therapy for Central Nervous System Disorders - Drug Profile
Stem Cell Therapy for Neurodegenerative Diseases - Drug Profile
Stem Cell Therapy for Spinal Cord Injury - Drug Profile
Stem Cell Therapy for Spinal Cord Injury - Drug Profile
Stem Cell Therapy for Spinal Cord Injury, Alzheimer's Disease, Progressive Supranuclear Palsy and Cerebral Palsy - Drug Profile
Synthetic Peptide to Antagonize PTPRS for Spinal Cord Injury - Drug Profile
Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders and Infectious Disease - Drug Profile
TG-N - Drug Profile
UH-0113 - Drug Profile
UH-0213 - Drug Profile
VX-210 - Drug Profile
Xcel-hNu - Drug Profile
Xcel-hNuP - Drug Profile
Spinal Cord Injury - Dormant Projects
Spinal Cord Injury - Discontinued Products
Spinal Cord Injury - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Spinal Cord Injury, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Spinal Cord Injury - Pipeline by AbbVie Inc, H2 2017
Spinal Cord Injury - Pipeline by Acorda Therapeutics Inc, H2 2017
Spinal Cord Injury - Pipeline by Aevi Genomic Medicine Inc, H2 2017
Spinal Cord Injury - Pipeline by Apollo Endosurgery Inc, H2 2017
Spinal Cord Injury - Pipeline by Asterias Biotherapeutics Inc, H2 2017
Spinal Cord Injury - Pipeline by Athersys Inc, H2 2017
Spinal Cord Injury - Pipeline by BioArctic AB, H2 2017
Spinal Cord Injury - Pipeline by BioAxone BioSciences Inc, H2 2017
Spinal Cord Injury - Pipeline by Biogen Inc, H2 2017
Spinal Cord Injury - Pipeline by CSL Ltd, H2 2017
Spinal Cord Injury - Pipeline by CSPC Pharmaceutical Group Limited, H2 2017
Spinal Cord Injury - Pipeline by Genervon Biopharmaceuticals LLC, H2 2017
Spinal Cord Injury - Pipeline by Hemostemix Inc, H2 2017
Spinal Cord Injury - Pipeline by Histocell SL, H2 2017
Spinal Cord Injury - Pipeline by K-Stemcell Co Ltd, H2 2017
Spinal Cord Injury - Pipeline by Kadimastem Ltd, H2 2017
Spinal Cord Injury - Pipeline by Kringle Pharma Inc, H2 2017
Spinal Cord Injury - Pipeline by MandalMed Inc, H2 2017
Spinal Cord Injury - Pipeline by Mapreg SAS, H2 2017
Spinal Cord Injury - Pipeline by Neuralstem Inc, H2 2017
Spinal Cord Injury - Pipeline by Neuronax SAS, H2 2017
Spinal Cord Injury - Pipeline by New World Laboratories Inc, H2 2017
Spinal Cord Injury - Pipeline by Pharmicell Co Ltd, H2 2017
Spinal Cord Injury - Pipeline by PixarBio Corp, H2 2017
Spinal Cord Injury - Pipeline by RDD Pharma Ltd, H2 2017
Spinal Cord Injury - Pipeline by RespireRx Pharmaceuticals Inc, H2 2017
Spinal Cord Injury - Pipeline by SanBio Inc, H2 2017
Spinal Cord Injury - Pipeline by Spectrum Pharmaceuticals Inc, H2 2017
Spinal Cord Injury - Pipeline by Stemedica Cell Technologies Inc, H2 2017
Spinal Cord Injury - Pipeline by TissueGene Inc, H2 2017
Spinal Cord Injury - Pipeline by Tumorend LLC, H2 2017
Spinal Cord Injury - Pipeline by Vertex Pharmaceuticals Inc, H2 2017
Spinal Cord Injury - Pipeline by Vicore Pharma AB, H2 2017
Spinal Cord Injury - Dormant Projects, H2 2017
Spinal Cord Injury - Dormant Projects, H2 2017 (Contd..1), H2 2017
Spinal Cord Injury - Dormant Projects, H2 2017 (Contd..2), H2 2017
Spinal Cord Injury - Dormant Projects, H2 2017 (Contd..3), H2 2017
Spinal Cord Injury - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Spinal Cord Injury, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

AbbVie Inc
Acorda Therapeutics Inc
Aevi Genomic Medicine Inc
Apollo Endosurgery Inc
Asterias Biotherapeutics Inc
Athersys Inc
BioArctic AB
BioAxone BioSciences Inc
Biogen Inc
CSL Ltd
CSPC Pharmaceutical Group Limited
Genervon Biopharmaceuticals LLC
Hemostemix Inc
Histocell SL
K-Stemcell Co Ltd
Kadimastem Ltd
Kringle Pharma Inc
MandalMed Inc
Mapreg SAS
Neuralstem Inc
Neuronax SAS
New World Laboratories Inc
Pharmicell Co Ltd
PixarBio Corp
RDD Pharma Ltd
RespireRx Pharmaceuticals Inc
SanBio Inc
Spectrum Pharmaceuticals Inc
Stemedica Cell Technologies Inc
TissueGene Inc
Tumorend LLC
Vertex Pharmaceuticals Inc
Vicore Pharma AB
Skip to top


Traumatic Brain Injury - Pipeline Review, H2 2017 US$ 2,000.00 Jul, 2017 · 252 pages

Ask Your Question

Spinal Cord Injury - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: